上海医药：公司收购上海和黄后，双方整合大品种开发、循证医学研究、中药国际化等核心资源

证券日报07-29 19:58

证券日报网7月29日讯，上海医药在接受调研时表示，公司收购上海和黄后，双方依托彼此在产业链和渠道网络等方面的资源优势，整合大品种开发、循证医学研究、中药国际化等核心资源，赋能集团中药业务高质量发展。一方面，公司将借鉴融合上海和黄在中药大品种创新改良方面的丰富经验与管理体系，利用循证医学等手段，加快培育胃复春、八宝丹、冠心宁等系列名优中药品种。另一方面，上海和黄在心血管领域所积累的垂直优势，也将...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2655860648?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-29 19:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655860648","market":"us","top_or_hot":-1,"title":"上海医药：公司收购上海和黄后，双方整合大品种开发、循证医学研究、中药国际化等核心资源","media":"证券日报","content":"<div>\n<p>证券日报网7月29日讯 ，上海医药在接受调研时表示，公司收购上海和黄后，双方依托彼此在产业链和渠道网络等方面的资源优势，整合大品种开发、循证医学研究、中药国际化等核心资源，赋能集团中药业务高质量发展。一方面，公司将借鉴融合上海和黄在中药大品种创新改良方面的丰富经验与管理体系，利用循证医学等手段，加快培育胃复春、八宝丹、冠心宁等系列名优中药品种。另一方面，上海和黄在心血管领域所积累的垂直优势，也将...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202607293825275880.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>上海医药：公司收购上海和黄后，双方整合大品种开发、循证医学研究、中药国际化等核心资源</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n上海医药：公司收购上海和黄后，双方整合大品种开发、循证医学研究、中药国际化等核心资源\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-29 19:58 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202607293825275880.html><strong>证券日报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券日报网7月29日讯 ，上海医药在接受调研时表示，公司收购上海和黄后，双方依托彼此在产业链和渠道网络等方面的资源优势，整合大品种开发、循证医学研究、中药国际化等核心资源，赋能集团中药业务高质量发展。一方面，公司将借鉴融合上海和黄在中药大品种创新改良方面的丰富经验与管理体系，利用循证医学等手段，加快培育胃复春、八宝丹、冠心宁等系列名优中药品种。另一方面，上海和黄在心血管领域所积累的垂直优势，也将...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202607293825275880.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0099","symbol_name":"上海本地重组","start_time":0,"source_url":"http://finance.eastmoney.com/a/202607293825275880.html","article_id":"2655860648","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607293825275880.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2655860648","pubTimestamp":1785326280,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"证券日报网7月29日讯，上海医药在接受调研时表示，公司收购上海和黄后，双方依托彼此在产业链和渠道网络等方面的资源优势，整合大品种开发、循证医学研究、中药国际化等核心资源，赋能集团中药业务高质量发展。一方面，公司将借鉴融合上海和黄在中药大品种创新改良方面的丰富经验与管理体系，利用循证医学等手段，加快培育胃复春、八宝丹、冠心宁等系列名优中药品种。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"601607":"上海医药","BK0099":"上海本地重组","BK0097":"医药电商","BK0028":"国家队","BK0020":"浦东新区","BK1197":"保健护理产品经销商","BK0183":"MSCI概念","02607":"上海医药","BK0209":"零售","BK0188":"融资融券","BK0012":"证金概念","BK0196":"行业龙头","BK0175":"白马股","BK0187":"一线龙头","BK0184":"上海国资改革"},"translate_title":"Shanghai Pharmaceuticals: After the company acquired Shanghai Hutchison, the two parties integrated core resources such as large variety development, evidence-based medicine research, and internationalization of traditional Chinese medicine","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1.5,"02607":1.5},"content_text":"证券日报网7月29日讯 ，上海医药在接受调研时表示，公司收购上海和黄后，双方依托彼此在产业链和渠道网络等方面的资源优势，整合大品种开发、循证医学研究、中药国际化等核心资源，赋能集团中药业务高质量发展。一方面，公司将借鉴融合上海和黄在中药大品种创新改良方面的丰富经验与管理体系，利用循证医学等手段，加快培育胃复春、八宝丹、冠心宁等系列名优中药品种。另一方面，上海和黄在心血管领域所积累的垂直优势，也将助力公司相关研发管线与产品线的商业化进程，公司首个获批的1类新药苹果酸司妥吉仑片（商品名：信妥安®）由上海和黄营销团队负责商业化，而基于麝香保心丸的成功经验，该团队在心血管领域拥有极为丰富的学术推广及大品种培育经验。截至6月末，信妥安已完成29个省份挂网工作，线下渠道销售覆盖300余家终端，并通过2026医保目录初步形式审查（医保局已公示）。（文章来源：证券日报）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655860648","isCrawlerRequest":true}